Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine vs. Dexmedetomidine in Agitated Delirium
NCT04758936Phase 4
Key facts
- Status
- Unknown
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Countries
- 1
- Sponsor
- Erasmus Hospital
- Modality
- Small Molecules
- Conditions
- delirium
01
Overview
Phase 4, randomised, open-label trial in delirium comparing Clonidine Arm with Dexmedetomidine Arm (2 arms). Primary endpoint: Hemodynamic tolerance at 7 days. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Clonidine Arm
Clonidine infusion titrated based on sedation and analgesia scales.
Dexmedetomidine Arm
Dexmedetomidine infusion titrated based on sedation and analgesia scales.
03
Who it enrols
Patients with agitated delirium confirmed by CAM-ICU requiring mechanical restraint or sedation, excluding those with severe organ failure, neurological issues, or hemodynamic instability.
04
Endpoints
Primary
Hemodynamic tolerance
Secondary
Number of living days without ventilation over 28 days
Time to obtain a sedative sedation score (NICS -1 to 1)
Time to obtain a first CAM-ICU test indicating the absence of delirium
Duration of delirium by evaluation CAM-ICU
Use of other sedative and psychotropic medications
Number of catheters / agitation extubation
Number of patients with tracheostomy
Daily assessment of organ dysfunction by SOFA score
Beyond the preview
Go deeper on NCT04758936.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758936.